Acute Myeloid Leukemia (AML) Therapeutics

Acute Myeloid Leukemia (AML) Therapeutics

Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach US$1.7 Billion by 2030

The global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$688.1 Million in the year 2023, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2023-2030. Cytarabine, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$592.7 Million by the end of the analysis period. Growth in the Anthracycline Drugs segment is estimated at 14.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$245.7 Million While China is Forecast to Grow at 15.2% CAGR

The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$245.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$151.0 Million by the year 2030 trailing a CAGR of 15.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.1% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.

Global Acute Myeloid Leukemia (AML) Therapeutics Market - Key Trends & Drivers Summarized

Acute Myeloid Leukemia (AML) is a type of cancer that originates in the bone marrow and rapidly progresses to affect the blood and other parts of the body. It is characterized by the rapid growth of abnormal white blood cells that interfere with normal blood cell production. AML is most commonly diagnosed in older adults, but it can occur at any age. The treatment of AML involves a combination of chemotherapy, targeted therapy, and in some cases, stem cell transplantation. Some of the chemotherapy types are: Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites, among other types. Over the years, advancements in understanding the genetic and molecular basis of AML have led to the development of more effective and personalized treatment options, improving patient outcomes and survival rates.

Recent advancements in AML therapeutics have focused on targeted therapies and immunotherapies, which aim to specifically target cancer cells while minimizing damage to healthy cells. Targeted therapies, such as FLT3 inhibitors and IDH inhibitors, have shown promise in treating specific genetic mutations associated with AML. Immunotherapies, including monoclonal antibodies and immune checkpoint inhibitors, are being investigated for their potential to enhance the body`s immune response against leukemia cells. The development of these novel therapies has been facilitated by advancements in genomic profiling and molecular diagnostics, allowing for more precise identification of therapeutic targets. Clinical trials and research efforts continue to explore new treatment strategies and combinations to further improve outcomes for AML patients.

The growth in the Acute Myeloid Leukemia (AML) therapeutics market is driven by several factors, including advancements in genomic research, increasing prevalence of AML, and the development of novel targeted therapies. The growing understanding of the genetic and molecular landscape of AML has paved the way for the development of personalized treatment approaches. The rising incidence of AML, particularly among the aging population, has increased the demand for effective and innovative therapies. Technological advancements in diagnostics and drug development have led to the introduction of new targeted therapies and immunotherapies, offering hope for improved survival rates and quality of life for AML patients. Additionally, government funding and support for cancer research, along with the involvement of pharmaceutical companies in developing cutting-edge treatments, are contributing to the market`s growth. As these trends continue, the AML therapeutics market is expected to expand, driven by the need for more effective and personalized treatment options.

Select Competitors (Total 112 Featured) -

• Amgen, Inc.
• Astellas Pharma, Inc.
• AbbVie, Inc.
• A. Menarini Industrie Farmaceutiche Riunite Srl
• Actinium Pharmaceuticals, Inc.
• Aptose Biosciences, Inc.
• Aprea Therapeutics
• Astex Pharmaceuticals, Inc.
• AB Science SA
• Aptevo Therapeutics
• Ascentage Pharma
• arGEN-X
• Accent Therapeutics
• Arcellx
• Amphivena Therapeutics

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.